Isoniazid inactivation was studied in 60 patients with concomitant diseases (pulmonary tuberculosis and diabetes mellitus). Thirty three patients had type 1 diabetes mellitus (Group 1) and 27 had type 2 (Group 2). Weak isoniazid inactivators were 81.2% in Group 1 and 51.9% (p < 0.02), which was much greater than those in patients with tuberculosis alone. The distinctive features of isoniazid metabolism in patients with diabetes mellitus were decreased acetylation of the drug and appropriate increased splitting and oxidation. In patients with type 1 diabetes mellitus, the prevalence of weak drug inactivation may both promote higher chemotherapeutical efficiency and enhance the likelihood of side effects.
Download full-text PDF |
Source |
---|
PLoS One
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Objectives: The coronary heart disease (CHD) can influence the development of several diseases. The presence of CHD is correlated to a higher incidence of concurrent diabetic retinopathy (DR) in previous study. Herein, we aim to analyze the relationship between the CHD severity and following DR with different severity.
View Article and Find Full Text PDFPLoS One
January 2025
School of Human Nutrition, McGill University, Montreal, Québec, Canada.
Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. While fear of hypoglycemia during physical activity is well documented, research on hyperglycemia-related anxiety (HRA) is limited. HRA refers to the heightened fear that hyperglycemia-related symptoms will impair functioning.
View Article and Find Full Text PDFPLoS One
January 2025
Population Health Research Institute, St George's, University of London, London, United Kingdom.
Aims: Type 2 diabetes (T2D) is more common in certain ethnic groups. This systematic review compares mortality risk between people with T2D from different ethnic groups and includes recent larger studies.
Methods: We searched nine databases using PRISMA guidelines (PROSPERO CRD42022372542).
Endocrinology
January 2025
Department of Pediatrics, Divisions of Neonatology & Developmental Biology and Endocrinology, Neonatal Research Center of the UCLA Children's Discovery & Innovation Institute at the David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1752.
To determine the basis for perinatal nutritional mismatch causing metabolic dysfunction associated steatotic liver disease (MASLD) and diabetes mellitus, we examined adult phenotype, hepatic transcriptome, and pancreatic β-islet function. In prenatal caloric restricted rat with intrauterine growth restriction (IUGR) and postnatal exposure to high fat with fructose (HFhf) or high carbohydrate (RC), we investigated male and female IUGR-Hfhf and IUGR-RC, versus HFhf and CON offspring. Males more than females displayed adiposity, glucose intolerance, insulin resistance, hyperlipidemia, hepatomegaly with hepatic steatosis.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
January 2025
Abbott Diabetes Care, Mississauga, Ontario, Canada.
Background: Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and continuous glucose monitoring (CGM) have been shown to improve glycated hemoglobin A1c (A1c) levels among patients with type 2 diabetes mellitus (T2DM). Recently, a US real-world study found statistically significant improvements in A1c levels among patients using GLP-1 RA and a CGM device, compared with a matched cohort receiving only GLP-1 RA.
Objectives: To assess the cost-effectiveness from a US payer perspective of initiating CGM (FreeStyle Libre Systems) in people living with T2DM using a GLP-1 RA therapy, compared with GLP-1 RA alone.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!